drugset / Trial / NCT00640016
A Study to Assess the Efficacy, Safety, and Tolerability of CAT-354 in Subjects With Asthma
Phase 2
Terminated
14 enrolled
MedImmune LLC
Cambridge Antibody Technology · collabPRA Health Sciences · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
To investigate the effects of CAT-354 on airway hyper-responsiveness (AHR) in uncontrolled asthma.
Timeline
- Start
- 2008-01
- Primary completion
- 2008-07
- Completion
- 2008-07
Outcome
Outcome not reported
Stopped (Enrollment): “The study was terminated prematurely by the sponsor due to slow recruitment.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tralokinumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Tralokinumab | Monoclonal antibody | 5 mg/kg | Intravenous |